Tens of thousands of lives in the United States are being lost or forever changed because of a glaring gap in preventive care: patients eligible for cholesterol-lowering drugs, like statins, simply aren’t getting them.

A new national study published in the Journal of General Internal Medicine reveals a striking public health failure. If everyone eligible for these medications were taking them, researchers estimate the country could prevent more than 39,000 deaths annually, along with up to 100,000 non-fatal heart attacks and 65,000 strokes.

Yet, the numbers tell a frustrating story. Among Americans aged 40 to 75 who’ve never suffered a heart attack or stroke but meet clinical guidelines for statin use, fewer than 1 in 4 are actually taking them. Even among those who have survived a cardiovascular event — and are at high risk for recurrence — a full third are not prescribed the drugs proven to save their lives.

“These are life-altering events that don’t need to happen,” said Dr. Caleb Alexander, lead author of the study and a professor of epidemiology at Johns Hopkins Bloomberg School of Public Health. “We’re not talking about some rare or experimental therapy — we’re talking about statins, which are well-established, safe, and affordable.”

Researchers based their findings on health survey data from nearly 5,000 participants collected by the CDC between 2013 and 2020. Each participant’s cholesterol levels and cardiovascular risk profiles were evaluated to determine whether they should be on statins according to U.S. guidelines.

The implications go beyond personal tragedy. In addition to lives lost, researchers estimate that widespread statin use could reduce the need for nearly 88,000 invasive heart procedures annually, including bypass surgeries and angioplasties. The ripple effect would save the health care system over $30 billion every year.

So why the gap?

“There’s no single culprit,” said Dr. Alexander. “We’re dealing with a mix of systemic challenges — from inconsistencies in physician training and clinical follow-through, to patients wary of side effects, to broader issues like health care access and affordability. Then there’s the reality of busy clinics where implementing guidelines can fall by the wayside.”

Dr. Seth Martin, a senior author of the study and a cardiologist at Johns Hopkins University School of Medicine, believes this is a crisis hiding in plain sight. “High cholesterol is a silent killer,” he said. “Millions walk around with dangerously elevated LDL levels without knowing it, and when it is diagnosed, treatment is too often delayed or neglected.”

Statins, which lower LDL or “bad” cholesterol, have been shown to significantly reduce the risk of heart attack, stroke, and premature death. The study estimates that with proper use, average LDL levels across the eligible population could fall dramatically, cutting cardiovascular risk by as much as 27%.

The takeaway? Cholesterol management isn’t just a numbers game — it’s a matter of national urgency.

“Closing this gap isn’t just good medicine,” Martin added. “It’s a moral and economic imperative.”